Multiplex Assay Kit for Inducible T-Cell Co Stimulator (ICOS) ,etc. by FLIA (Flow Luminescence Immunoassay)

CD278; AILIM; Inducible T-Cell Costimulator; Activation-Inducible Lymphocyte Immunomediatory Molecule

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Inducible T-Cell Co Stimulator (ICOS) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Inducible T-Cell Co Stimulator (ICOS) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Inducible T-Cell Co Stimulator (ICOS) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Inducible T-Cell Co Stimulator (ICOS) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 91-98 95
EDTA plasma(n=5) 84-91 88
heparin plasma(n=5) 83-99 91
sodium citrate plasma(n=5) 92-99 96

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Inducible T-Cell Co Stimulator (ICOS) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Inducible T-Cell Co Stimulator (ICOS) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Inducible T-Cell Co Stimulator (ICOS) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 94-104% 98-105% 83-98% 94-103%
EDTA plasma(n=5) 90-98% 83-103% 80-93% 78-103%
heparin plasma(n=5) 82-92% 97-105% 89-101% 82-101%
sodium citrate plasma(n=5) 80-91% 89-96% 92-105% 98-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:ICOS) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Archives of Dermatological Research Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis Pubmed: 23053221
DNA Cell Biol. Effect of soluble inducible costimulator level and its polymorphisms on age-related macular degeneration. Pubmed: 24083358
Rheumatology Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis Pubmed: 23024058
Br J Haematol Inducible T‐cell co‐stimulator (ICOS) and ICOS ligand are novel players in the multiple‐myeloma microenvironment Pubmed:34954822
Diagnostics (Basel) Increased Levels of ICOS and ICOSL Are Associated to Pulmonary Arterial Hypertension in Patients Affected by Connective Tissue Diseases Pubmed:35328257
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPA777Hu01 Recombinant Inducible T-Cell Co Stimulator (ICOS) Positive Control; Immunogen; SDS-PAGE; WB.
PAA777Hu01 Polyclonal Antibody to Inducible T-Cell Co Stimulator (ICOS) WB; IHC; ICC; IP.
FAA777Hu01 Anti-Inducible T-Cell Co Stimulator (ICOS) Polyclonal Antibody Flow cytometry.
LAA777Hu81 FITC-Linked Polyclonal Antibody to Inducible T-Cell Co Stimulator (ICOS) WB; IHC; ICC; IF.
LAA777Hu71 Biotin-Linked Polyclonal Antibody to Inducible T-Cell Co Stimulator (ICOS) WB; IHC; ICC.
FAA777Hu41 PE-Linked Anti-Inducible T-Cell Co Stimulator (ICOS) Polyclonal Antibody Flow cytometry.
FAA777Hu51 APC-Linked Anti-Inducible T-Cell Co Stimulator (ICOS) Polyclonal Antibody Flow cytometry.
FAA777Hu81 FITC-Linked Anti-Inducible T-Cell Co Stimulator (ICOS) Polyclonal Antibody Flow cytometry.
MAA777Hu22 Monoclonal Antibody to Inducible T-Cell Co Stimulator (ICOS) WB; IHC; ICC; IP.
RAA777Hu21 Recombinant Antibody to Inducible T-Cell Co Stimulator (ICOS) WB; IFC; IHC; IP.
SEA777Hu ELISA Kit for Inducible T-Cell Co Stimulator (ICOS) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA777Hu Multiplex Assay Kit for Inducible T-Cell Co Stimulator (ICOS) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.